Abstract
Tuberculosis (TB) is a serious infection and one of the oldest known human conditions. Antituberculosis drug-induced hepatotoxicity (DIH) is the most common adverse effect that may lead to interruption of therapy. Many possible risk factors have been reported in some studies to play a role in the incidence of DIH and few studies suggested that baseline hypoalbuminemia can predict the development of DIH. The objective was: to assess the association between baseline hypoalbuminemia (not due to HI er disease) and the incidence of DIH. A retrospective study conducted on patients diagnosed with tuberculosis. The patients were divided into two groups; cases and controls, in the cases group we included the patients who developed DIH, while in the controls group, we included all the patients who have been treated for the full duration without any evidence of hepatotoxicity. Out of 466 patients, 63 developed DIH (cases) and 383 were treated completely without any evidence of hepatotoxicity (controls). In the study subjects 248 (64.8%) of the Non DIN patients were aged >= 35 years, 9.1% of the Non DIH patients were smokers. The most commonly reported co-morbidities among the Non DIH and DIH patients were diabetes, Hypertension, Cardiovascular disease. Among the Non DIH patients 49.3% of them had Pulmonary 50.7% of Extra Pulmonary Site of TB. Hypoalbuminemia was the only significant predictor of the occurrence of DIH (95% CI, 1.7 to 5.6; odds ratio, 3.1; p < 0.001). Baseline hypoalbuminemia (< 35 g/L) was a significant risk factor for the development of DIH.